Does Florida Medicaid cover Wegovy? Check the plan, use, and form
There is no blanket yes or no. Florida's October 2026 preferred drug list does not name Wegovy, while one Florida Medicaid managed-plan policy describes conditional coverage for certain non-weight-loss uses and excludes weight-loss-only use. The exact plan, indication, form, and authorization decide the question.
Florida Medicaid Wegovy coverage cannot be answered from the drug name alone. The state’s October 2026 preferred drug list does not list Wegovy, but that absence is not a universal denial: at least one Florida Medicaid managed-plan policy describes conditional authorization for specified cardiovascular and injection-only MASH uses while excluding weight-loss-only use. Identify the member’s exact plan, the prescriber’s documented indication, Wegovy tablet versus injection, and the current authorization decision.1234
This is a dated coverage-record guide. A preferred list, a clinical policy, and an actual pharmacy claim answer different questions. Coverage documents can change; a reader should use their current member plan and its pharmacy channel for a final answer. Treomark does not know whether any listed weight clinic accepts a particular Medicaid plan.
The state list is a starting record, not every plan’s answer
Florida’s Agency for Health Care Administration publishes a preferred drug list. The version effective October 1, 2026 does not name Wegovy, while it lists other GLP-1 products in their own categories.1 The accompanying state GLP-1 prior-authorization criteria name certain diabetes products and diagnoses, not a general Wegovy weight-loss benefit.2 This supports a narrow statement about those state documents. It does not prove that every managed-care member, exception request, or distinct indication has the same outcome.
The state PDL itself warns that a listed name does not guarantee that every national drug code is reimbursable.1 The reverse is also important for interpretation: a product omitted from a preferred list cannot be turned into a complete, plan-independent coverage verdict without checking the member’s actual benefit and policy.
| Document | What it can show | What it cannot show alone |
|---|---|---|
| State PDL | Whether the named product appears in that dated preferred list | Every Medicaid managed-plan or exception result |
| State GLP-1 criteria | Which named diabetes products and conditions those criteria address | Wegovy coverage for every different indication |
| Member's managed-plan policy | The plan's current product, indication and documentation criteria | That the individual request has been approved |
| Authorization or claim response | How the exact request was decided | A permanent rule for future plan years or products |
A real Florida managed-plan example changes the answer
Aetna Better Health’s current Medicaid policy is explicitly marked as applying to Florida. It excludes Wegovy or Zepbound when the requested use is weight loss only, while describing conditional Wegovy coverage for certain other purposes, including a cardiovascular indication and an injection-only MASH pathway.3 The Florida provider portal links to the pharmacy authorization process.4
That example proves why “Florida Medicaid never covers Wegovy” is too broad. It does not mean Aetna approves every request within those categories, that other Florida plans share the policy, or that a person with a diagnosis automatically meets the plan’s detailed documentation criteria. The plan document itself distinguishes formulation and indication. A Wegovy tablet is not silently interchangeable with injection under a policy that names injection for a particular use.
MASH is a specialist liver-disease indication with its own FDA and coverage boundaries. A local weight-management service listing does not imply that it evaluates or treats MASH. The four-brand indication guide explains why product and indication must be read at the same level as the policy. This article does not evaluate whether anyone meets a clinical criterion.
Verify the member’s real benefit in the right order
First capture the Medicaid program and managed-plan name from the member’s current enrollment record. Then identify the exact Wegovy formulation and the prescriber’s documented indication. Request the plan’s current formulary and medical or pharmacy policy for that combination, plus the authorization channel and any written decision already made. The prescriber and plan, not a clinic marketing page, establish and adjudicate those facts.
Ask the plan whether the question is a preferred-list issue, an excluded benefit, a prior-authorization requirement, a formulary exception, or a claim-processing issue. Those are different records and should not be merged into “Wegovy is covered” or “Wegovy is denied.” If a request is denied, the reason on the written notice matters more than an online forum’s account of another person’s outcome.
Do not substitute Medicare rules. The Medicare GLP-1 Bridge is a separate temporary federal program for eligible people with Medicare Part D drug coverage. It does not alter a Florida Medicaid member’s managed-plan benefit by itself.
A useful clinic conversation
Ask a weight-management practice which named product it proposes, which diagnosis it will document, who writes the prescription, and whether it can submit to the person’s specific Florida Medicaid plan. A clinic might provide medical visits while the medicine is dispensed through a separate pharmacy benefit; ask which charges and entities are involved. The weight-program cost guide helps keep visit charges apart from drug coverage.
Bring the member’s current plan name, proposed Wegovy form, and documented indication to the coverage conversation. Ask the weight-management practice which authorization it can actually submit, then retain the plan’s written determination. A state list alone cannot settle a managed-plan claim.
Sources
- Florida Agency for Health Care Administration. Florida Medicaid Preferred Drug List, effective October 1, 2026. State preferred list omits the Wegovy brand; absence from this list is not proof of every managed-plan or exception outcome. Accessed .
- Florida Agency for Health Care Administration. GLP-1 receptor agonist prior authorization criteria, October 2026. Current state criteria name certain diabetes GLP-1 products; these criteria do not themselves decide a Wegovy claim under every Medicaid managed plan. Accessed .
- Aetna Better Health. Wegovy cardiovascular and Zepbound sleep-apnea coverage policy, effective September 2026. Original plan policy explicitly applies to Florida, excludes weight-loss-only use, and describes conditional Wegovy injection authorization for MASH and product-specific cardiovascular criteria; example, not universal Medicaid coverage. Accessed .
- Aetna Better Health Florida. Pharmacy prior authorization for Florida providers. Current Florida managed-plan entry point linking the original policy and authorization process; member benefit and policy version must still be checked. Accessed .